Scientific references TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial (NEJM, 2023) Retatrutide for people with type 2 diabetes a Phase 2 trial (The Lancet, 2023) LY3437943 (retatrutide), a triple GIP/GLP-1/glucagon agonist Phase 1b trial MHRA: avoid illegal online weight-loss medicines MHRA Drug Safety Update: GLP-1 / GIP agonists pancreatitis warnings NICE TA875: Semaglutide for overweight and obesity NICE TA1026: Tirzepatide for overweight and obesity Incretin-based drugs and gallbladder / biliary disease (The Lancet) Final word for UK research customers A retatrutide 40mg pen is a pre-filled, ready-to-use research peptide with 40mg in the tank roughly 240 clicks, enough for many small doses or a handful of big ones
Brand K, Eisele T, Kreusel U, Page M, Page S, Haas M, Gerling A, Kaltschmidt C, Neumann FJ, Mackman N, Baeurele PA, Walli AK, Neumeier D
[7] Nach dem Absetzen einer GLP-1-Therapie kommt es jedoch hufig zu einer erneuten und raschen Gewichtszunahme und zur Verschlechterung der Herz-Kreislauf-Risikofaktoren
Pregnancy-related eating disorders Pregorexia is a term that refers to an eating disorder in which a great fear of pregnancy-related weight gain exists
Pain 135 ZanosP.MoaddelR.MorrisP
2009 ACCF/AHA focused update on perioperative beta blockade